Publications by authors named "Kenichi Kito"
Article Synopsis
- Fibrates can cause renal toxicity, which limits their use in patients with chronic kidney disease (CKD), but pemafibrate appears to be less harmful to kidney function.
- A study analyzed the effects of pemafibrate on 520 diabetic participants, assessing changes in kidney function over 52 weeks across different treatment options (ADD-ON, SWITCH, CTRL).
- Findings indicated that eGFR improved only in the SWITCH group, particularly in patients without severe kidney dysfunction, suggesting that switching to pemafibrate may benefit kidney function, but less so in patients with advanced renal issues.
Background: Pemafibrate has been reported to ameliorate lipid profiles and liver dysfunction. However, which patients derive benefit from the hepatoprotective effects of pemafibrate is unclear.
Methods: We conducted a sub-analysis of the PARM-T2D study where subjects with type 2 diabetes complicated by hypertriglyceridemia were prospectively treated with pemafibrate or conventional therapies for 52 weeks.
Pemafibrate, a novel selective peroxisome proliferator-activated receptor modulator, has beneficial effects on lipid metabolism. However, its effects on glucose metabolism in individuals with type 2 diabetes (T2DM) remain to be fully clarified. This was a subanalysis of the PARM-T2D study, a multicenter prospective observational study on the use of pemafibrate versus conventional therapy for 52 weeks in subjects with T2DM complicated with hypertriglyceridemia.
View Article and Find Full Text PDFAims: Pemafibrate, a novel selective peroxisome proliferator-activated receptor modulator, was shown to ameliorate lipid abnormalities in a phase III clinical trial of patients with type 2 diabetes mellitus (T2DM). However, its efficacy has not been demonstrated in real-world clinical practice in patients with T2DM.
Methods: We performed a multi-center prospective observational study of the use of pemafibrate in patients with T2DM and hypertriglyceridemia versus conventional therapy, with or without a fibrate.